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PTLD is a serious complication of iatrogenic immunosup-
pression, typically in the setting of solid organ trans-
plantation. For patients undergoing allogeneic stem cell
transplant. Potential risk factors include a T-cell depleted
graft, , HLA-mismatch, and GVHD.
Patients and Methods: We searched for PTLD occurrence
among 68 consecutive haplo-cord stem cell transplant re-
cipients treated at The University of Chicago in order to
describe its incidence, patient-, disease- and treatment-
related characteristics. Haplo-cord transplantation consisted
of a single cord blood unit augmented by a CD34+ selected
haploidentical G-CSF mobilized peripheral blood stem cell
graft from a related donor. Conditioning consisted of ﬂu-
darabine, melphalan and rabbit ATG. After the 3rd noted
PTLD, routine PCR monitoring of peripheral blood for EBV
was implemented.. Further evaluation for PTLD was as clin-
ically indicated, usually prompted by high EBV PCR copy
number with or without associated symptoms.
Results: 68 patients (med age 48 yrs, range 4-69) underwent
haplo-cord transplantation; 8 patients (11.8%) were subse-
quently diagnosed with PTLD based on either clinical (n¼3)
or pathologically-proven (n¼5) criteria. All haploidentical
donors for the 8 PTLD patients had positive EBV serologies.
The median age of these 8 patients was 39 yrs (range, 28-51).
The median time from transplantation to development of
PTLD was 103 days (range, 68-164d). Among 4 patients with
a pathologically-conﬁrmed diagnosis, morphology was EBV+
monomorphic DLBCL, while a 5th patient had ﬂow cytom-
etry-based diagnosis showing a monomorphic lambda
restricted B-PTLD. All patients with biopsy-proven PTLD
were also strongly CD30+ with diffuse staining pattern. In 3
patients, the diagnosis of PTLDwas based on rapid rise of EBV
titers along with new onset adenopathy. The median EBV
viral load peak of all patients with PTLD was 2.39 million
(range, 23,000 to 10 million). There were no differences in
age, gender, or proportionwith lymphoid or myeloid disease.
All patients were treated with reduction of immunosup-
pression plus rituximab; one patient with CNS lesions was
treatedwith R-CHOP x 4 plus intrathecal methotrexate and is
currently in remission. 3 pts have died, including 2 deaths
due to PTLD.
Summary: PTLD is a common complication following haplo-
cord transplantation, likely related to ATG treatment and
HLA mismatch in the cord blood setting. We advocate close
EBV surveillance and prompt rituximab treatment for this
approach. The observation that CD30 positivity is common
raises the possibility that brentuximab vedotin could be used
along with other standard approaches in management.349
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Chronic Graft versus Host Disease (CGVHD) is an autoim-
mune-like disorder that remains the main cause of non-
relapse morbidity and mortality following allogeneic
hematopoietic stem cell transplantation (alloHSCT), yet its
pathogenic mechanisms remain poorly understood. To
identify the systemic cytokine pathways supporting the
development and persistence of CGVHD, we performed
microarray analysis on sorted monocytes from normal con-
trols (NC) and patients with severe cutaneous involvement,
including both lichenoid and sclerotic CGVHD. Monocytes
were chosen as in vivo reporter cells, capable of upregulating
distinct patterns of gene expression in response to different
cytokines. Two main pathways were determined to be
signiﬁcantly upregulated. (1) Interferon (IFN)-inducible
genes including those involved in signaling, anti-viral func-
tion, lymphocyte homeostasis and trafﬁcking, apoptosis and
antigen uptake and presentation (STAT1, GBP1, IL15,
TNFSF13B, CXCL10, TNFSF10, FCGR1A, MSR1, TAP1). (2) Upre-
gulation of innate immune TLR/RIG1/CLR receptors that can
respond to pathogens or cell damage by triggering IFN pro-
duction and inﬂammasome formation (TLR2, TLR4, AIM2,
DDX58, IFIH1, CLEC4E). Based on the microarray proﬁle, we
designed a multiplex RNA analysis probe set to test gene
expression in monocytes from (1) CGVHD patients with a
broad range of organ involvement, (2) alloHSCT patients
without clinical signs of CGVHD (NP) and (3) normal controls
(NC). The genes involved in IFN induced and innate immune
pathways that were identiﬁed by microarray analysis were
veriﬁed in this more quantitative analysis in 75 CGVHD, 14
NP and 20 NC; comparable upregulation of these pathways
was found in patients with extensive lichenoid or sclerotic
CGVHD. Furthermore, these pathways were substantiated in
ELISA assays by elevated levels of IFN induced chemokines
(CXCL9, CXCL10) and cytokines (BAFF) in CGVHD patient
plasma, and were consistent with increased levels of Type I
Interferon producing cells and IFN-induced factors (MXA,
CXCL9) in inﬂammatory inﬁltrates in CGVHD targeted tis-
sues. These results suggest that IFN induced by the innate
immune system’s response to damage associated molecular
patterns (DAMP) could initiate and contribute to a sustained
inﬂammatory process in CGVHD.350
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MDS/MPN are hematopoietic malignancies with both
dysplastic and proliferative features. Therapeutic options are
limited, with low probabilities and durations of remission.
Allogeneic HCT is the only potentially curative treatment;
however few data on outcomes and risk factors for survival
inMDS/MPN have been reported.We thus evaluated our HCT
experience with MDS/MPN.
